FDA To Name IoM Safety Review Committee Members April 18
• By Steele Thomas and Andrew Kasper
The committee will then begin work on a safety study, which is expected to take approximately two years, agency officials say at FDA Science Board meeting. FDA also provides update on other safety initiatives – CDER Acting Deputy Director Throckmorton will chair agency’s Drug Safety Oversight Board.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
